Quest Diagnostics Incorporated
DGX
Κατάταξη σε μετοχές
#914
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus,... Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Τιμή μετοχής
$237.37
Κεφαλαιοποίηση
$26.20B
Αλλαγή (1 ημέρα)
0.29%
Αλλαγή (1 έτος)
28.56%
Χώρα
US
Εμπόριο Quest Diagnostics Incorporated (DGX)
Κατηγορία
Healthcare
Έσοδα για την Quest Diagnostics Incorporated (DGX)
Έσοδα τον Jun 2026 TTM: $11.56B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Quest Diagnostics Incorporated, τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $11.56B. Το 2024, η εταιρεία είχε έσοδα $9.87B αύξηση σε σχέση με τα έσοδα του έτους 2023, τα οποία ήταν $9.25B. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Quest Diagnostics Incorporated από 2000 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $11.56B | 4.76% |
| 2025 | $11.04B | 11.78% |
| 2024 | $9.87B | 6.70% |
| 2023 | $9.25B | -6.38% |
| 2022 | $9.88B | -8.39% |
| 2021 | $10.79B | 14.32% |
| 2020 | $9.44B | 22.15% |
| 2019 | $7.73B | 2.59% |
| 2018 | $7.53B | -2.31% |
| 2017 | $7.71B | 2.58% |
| 2016 | $7.52B | 0.29% |
| 2015 | $7.49B | 0.78% |
| 2014 | $7.44B | 4.04% |
| 2013 | $7.15B | -3.20% |
| 2012 | $7.38B | -1.70% |
| 2011 | $7.51B | 1.92% |
| 2010 | $7.37B | -1.16% |
| 2009 | $7.46B | 2.84% |
| 2008 | $7.25B | 8.12% |
| 2007 | $6.70B | 6.96% |
| 2006 | $6.27B | 13.90% |
| 2005 | $5.50B | 7.36% |
| 2004 | $5.13B | 8.20% |
| 2003 | $4.74B | 15.33% |
| 2002 | $4.11B | 13.24% |
| 2001 | $3.63B | 6.04% |
| 2000 | $3.42B | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $46.34B | 300.83% |
US
|
|
| $25.11B | 117.19% |
US
|
|
| $2.71B | -76.58% |
US
|
|
| - | - |
CN
|
|
| $7.37B | -36.23% |
US
|
